Citigroup Maintains Buy on WAVE Life Sciences, Lowers Price Target to $24

Benzinga Newsdesk www.benzinga.com Neutral 52.7%

Neg 0% Neu 52.7% Pos 0%

Citigroup analyst Samantha Semenkow maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $30 to $24.